CLINICAL_TRIALS
trial_result
· 2025-07-28
Clinical Trial Update: A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease [Phase 2]
Summary
Phase 2 study evaluating LY3372689 for Alzheimer's disease has completed, with results posted assessing safety, tolerability, and efficacy.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-07-28